- What is Unicycive Therapeutics, Inc.'s stock symbol?
Our stock is traded on the Nasdaq under the symbol UNCY.
- When was Unicycive Therapeutics, Inc. incorporated?
August 16, 2016
- When did Unicycive Therapeutics, Inc. become a public company?
July 13, 2021
- Where is Unicycive Therapeutics, Inc. located?
1975 W El Camino Real, Ste 204
Mountain View, CA 94040- When is Unicycive Therapeutics, Inc.'s fiscal year end?
December 31st
- Who is Unicycive Therapeutics, Inc.'s transfer agent?
Philadelphia Stock Transfer, Inc.
2320 Haverford Road
Ardmore, PA 19003- Who is Unicycive Therapeutics, Inc.'s independent auditor?
Grassi & Co. CPAs, P.C.
- What is Unicycive Therapeutics, Inc.'s mission?
Unicycive Therapeutics' mission is to identify, develop, and commercialize novel therapies that address significant unmet medical needs in kidney disease. Unicycive Therapeutics is committed to improving outcomes and quality of life for patients with chronic kidney disease, acute kidney injury, and related conditions — a population that Unicycive Therapeutics believes has been historically underserved by pharmaceutical innovation.
- Who founded Unicycive Therapeutics, Inc.?
Unicycive Therapeutics was founded in August 2016 by Shalabh Gupta, MD. Dr. Gupta serves as Founder, President, Chief Executive Officer, and Chairman of the Board of Unicycive Therapeutics. Before founding Unicycive Therapeutics, Dr. Gupta held leadership roles spanning clinical medicine, biotechnology equity research at UBS Investment Bank and Rodman & Renshaw, and commercial strategy at Genentech.
- Where is Unicycive Therapeutics, Inc. headquartered?
Unicycive Therapeutics is headquartered in Los Altos, California. From its Los Altos offices, Unicycive Therapeutics manages clinical development, regulatory strategy, and commercial readiness activities for the entire Unicycive Therapeutics kidney disease pipeline.
- Is Unicycive Therapeutics, Inc. publicly traded?
Yes — Unicycive Therapeutics is publicly traded on the Nasdaq Capital Market under the ticker symbol UNCY. Investors can access SEC filings, press releases, investor presentations, and event information through the Unicycive Therapeutics Investor Relations website at ir.unicycive.com.
- Which projects are Unicycive Therapeutics, Inc. currently working on?
Unicycive Therapeutics is currently advancing two investigational therapies focused on kidney disease:
Oxylanthanum carbonate (OLC) — the lead asset of Unicycive Therapeutics, a next-generation phosphate binder for hyperphosphatemia in patients with chronic kidney disease on dialysis. UNI-494 — a Unicycive Therapeutics program targeting conditions related to acute kidney injury, with initial focus on the prevention of delayed graft function (DGF) in kidney transplant patients. In addition, Unicycive Therapeutics continues to evaluate licensing opportunities for additional technologies and drug candidates targeting orphan diseases and other renal, liver, and metabolic conditions involving fibrosis and inflammation
- What is Oxylanthanum carbonate (OLC) and how does it work?
Oxylanthanum carbonate (OLC) is the lead investigational therapy of Unicycive Therapeutics. OLC is a next-generation lanthanum-based phosphate binder built on proprietary nanoparticle technology, which Unicycive Therapeutics is developing for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Like other phosphate binders, OLC works by binding dietary phosphate in the gastrointestinal tract, preventing absorption and helping reduce elevated serum phosphate — a serious complication of advanced kidney disease. Unicycive Therapeutics is developing OLC under the FDA's 505(b)(2) regulatory pathway, and the FDA has set a PDUFA target action date of June 29, 2026 for OLC.
- What makes Oxylanthanum carbonate (OLC) different from existing medications?
Unicycive Therapeutics designed Oxylanthanum carbonate (OLC) to address one of the most significant challenges in hyperphosphatemia management: patient adherence. Compared with currently available phosphate binders, OLC is intended to offer a meaningfully lower pill burden — fewer and smaller pills per dose, swallowed rather than chewed. The proprietary nanoparticle technology underpinning OLC is what differentiates the asset, and Unicycive Therapeutics has secured more than forty issued and granted patents globally to protect the OLC approach.
- What is UNI-494, and how does it work?
UNI-494 is the second investigational therapy in the pipeline of Unicycive Therapeutics. UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator. Because mitochondrial dysfunction plays a central role in the progression of acute and chronic kidney disease, Unicycive Therapeutics is developing UNI-494 with the goal of restoring mitochondrial function and protecting kidney tissue from injury. UNI-494 is being investigated by Unicycive Therapeutics for conditions related to acute kidney injury, with the initial indication being the prevention of delayed graft function (DGF) in kidney transplant patients.
- What is the development status of UNI-494?
Unicycive Therapeutics has successfully completed a Phase 1 dose-ranging safety study of UNI-494 in healthy volunteers, conducted in the United Kingdom. The U.S. Food and Drug Administration has granted UNI-494 Orphan Drug Designation for the prevention of delayed graft function (DGF) in kidney transplant patients — an indication for which there are currently no FDA-approved therapies. UNI-494 is also protected by issued patents in the United States and Europe, including patent protection extending through 2040, and Unicycive Therapeutics holds a wide range of additional patent applications worldwide.
- Where can I find information about clinical trials run by Unicycive Therapeutics, Inc.?
- Information on Unicycive Therapeutics clinical trials is available on ClinicalTrials.gov, where studies sponsored by Unicycive Therapeutics are registered along with eligibility criteria, study design, and site information. Patients, caregivers, and healthcare providers interested in current or upcoming Unicycive Therapeutics studies can also reach out directly through the contact channels listed on the Unicycive Therapeutics website.
- Where are Unicycive Therapeutics, Inc.'s clinical results published?
Clinical and scientific findings from Unicycive Therapeutics programs have been presented at leading nephrology meetings — including the National Kidney Foundation Spring Clinical Meeting and the European Renal Association (ERA) Congress — and published in peer-reviewed journals such as the Clinical Journal of the American Society of Nephrology. A complete and current list of Unicycive Therapeutics publications and scientific presentations is available in the Publications & Press section of the Unicycive Therapeutics website.
